New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Business Model:
Revenue: $18M
Employees: 2-10
Rankings
Industries / Tags:
Detailed New Leaf Venture Partners Information
Geographic Data
Address: Times Square Tower , 7 Times Square
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$400M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies. The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
Contact Phone:
+16468716400
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 11/2021 | Asimily | Venture Round | 0 |
| 10/2015 | Arvinas | Series B | 41.6M |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 4/2013 | Treato | Series B | 14.5M |
| 8/2022 | Arine | Series B | 0 |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 9/2011 | CardioKinetix | Series E | 21M |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 5/2014 | QPID Health | Series B | 12.3M |
| 9/2019 | Passage Bio | Series B | 110M |
| 2/2010 | Intrinsic Therapeutics | Venture Round | 18M |
| 6/2016 | CRISPR Therapeutics | Series B | 0 |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 9/2015 | Deciphera Pharmaceuticals | Series B | 75M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 3/2010 | Access Closure | Venture Round | 10M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 8/2018 | ReViral | Series B | 0 |
| 11/2015 | ObsEva | Series B | 60M |
| 11/2012 | Intarcia Therapeutics | Debt Financing | 50M |
| 2/2011 | Spine Wave | Series E | 17.5M |
| 11/2012 | Intarcia Therapeutics | Venture Round | 160M |
| 6/2010 | Altura Medical | Series A | 20M |
| 10/2009 | Aviir | Venture Round | 1M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 6/2013 | Aviir | Series B | 10M |
| 2/2011 | Spiracur | Series C | 35M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 9/2007 | Aviir | Series B | 11.3M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 8/2007 | ReShape Lifesciences | Series A | 3M |
| 12/2011 | Aviir | Venture Round | 10M |
| 1/2008 | Sopherion Therapeutics | Venture Round | 0 |
| 11/2012 | Advanced Cell Diagnostics | Series B | 12M |
| 3/2010 | Aureon Laboratories | Series C | - |
| 9/2012 | Karus Therapeutics | Series B | 7.6M |
| 4/2008 | IlluminOss Medical | Series B | 11M |
| 3/2007 | ProteoGenix | Series B | 20M |
| 10/2006 | VaxInnate | Series C | 40M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 1/2014 | TigerConnect | Series B | 23M |
| 6/2016 | Bluesight | Series C | 20.4M |
| 1/2015 | Bluesight | Series B | 12M |
| 9/2017 | Truveris | Series D | 25M |
| 3/2008 | Spiration | Series G | 18.5M |
| 4/2018 | Arvinas | Series C | 55M |
| 3/2013 | CardioKinetix | Series E | 23M |
| 12/2018 | Bellus Health | Post-IPO Equity | 26M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 5/2011 | Neuronetics | Series E | 30M |
| 4/2015 | Neuronetics | Series F | 0 |
| 7/2009 | Interlace Medical | Series C | 20.5M |
| 6/2017 | Neuronetics | Series G | 0 |
| 7/2013 | Versartis | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 4/2010 | Aureon Laboratories | Series D | 7M |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 4/2008 | Concert Pharmaceuticals | Series C | 0 |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 4/2006 | Spiration | Series F | 13.4M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 4/2008 | Stromedix | Series B | 25M |
| 2/2009 | ReShape Lifesciences | Post-IPO Equity | 20M |
| 1/2013 | Versartis | Series C | 0 |
| 11/2019 | AiCure | Series C | 24.5M |
| 4/2018 | Kyruus | Corporate Round | 0 |
| 9/2015 | Kyruus | Series C | 25M |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 6/2009 | Spiracur | Series B | 20.3M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 11/2017 | AiCure | Series B | 15M |
| 2/2013 | Aviir | Series B | 10M |
| 8/2008 | ProteoGenix | Series B | 8M |
| 12/2014 | CardioKinetix | Series F | 0 |
| 10/2012 | Presidio Pharmaceuticals | Venture Round | 8M |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 2/2014 | Versartis | Series E | 55M |
| 8/2006 | Interlace Medical | Series A | 750k |
| 3/2018 | Technology Will Save Us | Series A | 0 |
| 4/2015 | Edge Therapeutics | Series C | 56M |
| 2/2011 | Versartis | Series B | 21M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 2/2012 | Truveris | Series B | 10M |
| 6/2013 | Bluesight | Series A | 10.4M |
| 5/2009 | Visiogen | Series D | 40M |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 8/2019 | Qlaris Bio | Series A | 8.2M |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 6/2021 | Cleerly | Series B | 0 |
| 8/2020 | ReViral | Series C | 0 |
| 10/2012 | ReShape Lifesciences | Post-IPO Equity | 15M |
| 11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 6/2011 | Aviir | Venture Round | 3M |
| 5/2018 | IRLAB Therapeutics | Series A | 15.8M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 5/2007 | Interlace Medical | Series B | 3M |
| 7/2008 | Interlace Medical | Series B | 7M |
| 10/2020 | TigerConnect | Series D | 0 |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 8/2019 | Renovacor | Series A | 11M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 10/2007 | Relypsa | Series A | 33M |
| 11/2007 | Oriel Therapeutics | Venture Round | 26.5M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 8/2020 | Saniona | Post-IPO Equity | 0 |
| 6/2015 | Advanced Cell Diagnostics | Series C | 22M |
| 7/2018 | Alector | Series E | 133M |
| 9/2013 | Catalyst Pharmaceuticals Partners | Post-IPO Equity | 15.1M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 6/2020 | BrightInsight | Series B | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 10/2010 | Convergence Pharmaceuticals | Series A | 35.4M |
| 2/2011 | Chimerix | Series F | 45M |
| 4/2018 | Rallybio | Series A | 37M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 8/2015 | ReShape Lifesciences | Post-IPO Equity | 38M |
| 9/2019 | BrightInsight | Series A | 25M |
| 6/2016 | Kit Check | Series C | 0 |
| 10/2013 | Versartis | Series D | 0 |
| 4/2013 | iRhythm Technologies | Series D | 16M |
| 1/2012 | iRhythm Technologies | Private Equity Round | 12.2M |
| 5/2011 | iRhythm Technologies | Series C | 15M |
| 6/2013 | Kit Check | Series A | 10.4M |
| 7/2010 | Artisan Pharma | Series C | 0 |
| 9/2010 | Intarcia Therapeutics | Debt Financing | 5M |
| 10/2010 | WorldHeart | Venture Round | 25.3M |
| 6/2012 | Awarepoint | Venture Round | 14M |
| 10/2009 | Neuronetics | Series D | 0 |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 4/2020 | Rallybio | Series B | 0 |
| 1/2012 | Access Closure | Venture Round | 0 |
| 2/2007 | Visiogen | Venture Round | 24M |
| 10/2012 | Access Closure | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 3/2011 | Synageva BioPharma | Venture Round | 0 |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 2/2009 | ReShape Medical | Series B | 20M |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 1/2016 | AiCure | Series A | 12.3M |
| 8/2009 | SchoolCare | Series G | 14.4M |
| 3/2021 | BrightInsight | Series C | 101M |
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 6/2009 | VaxInnate | Series D | 30M |
| 12/2017 | Aptinyx | Series B | 70M |
| 9/2006 | Artisan Pharma | Series A | 39M |
| 7/2009 | Presidio Pharmaceuticals | Venture Round | 27M |
| 7/2013 | Karyopharm Therapeutics | Series B | 19M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 5/2018 | Neurana Pharmaceuticals | Series A | 0 |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 10/2009 | Synageva BioPharma | Series F | 0 |
| 10/2010 | Pearl Therapeutics | Series C | 69M |
| 9/2010 | Relypsa | Series B | 70M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2021 | Asimily | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 6/2021 | Cleerly | Series B | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 3/2021 | BrightInsight | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 8/2020 | ReViral | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
